The Down Under medical community is excited with the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing impressive results in early trials for managing obesity. This therapy https://veriea.com/2026/06/10/retatrutide-australia-the-next-generation-in-weight-loss/